Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 9, 2013

Primary Completion Date

November 24, 2015

Study Completion Date

July 30, 2018

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Abatacept

Trial Locations (13)

1138603

Local Institution, Bunkyo-ku

1620054

Local Institution, Shinjuku-ku

2328555

Local Institution, Yokohama

2360004

Local Institution, Yokohama

4748710

Local Institution, Oobu-shi

5698686

Local Institution, Takatsuki-shi

6500047

Local Institution, Kobe

8908520

Local Institution, Kagoshima

9030215

Local Institution, Nakagami-gun

9518520

Local Institution, Niigata

9893126

Local Institution, Sendai

0048618

Local Institution, Sapporo

0608648

Local Institution, Sapporo

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT01835470 - Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan | Biotech Hunter | Biotech Hunter